期刊
VACCINE
卷 38, 期 35, 页码 5653-5658出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2020.06.066
关键词
COVID-19; SARS-CoV-2; Spike protein; Vaccine
资金
- Beijing Science and Technology Commission [Z201100001020002]
- Bill & Melinda Gates Foundation [INV-005839]
- Bill and Melinda Gates Foundation [INV-005839] Funding Source: Bill and Melinda Gates Foundation
The COVID-19 outbreak has become a global pandemic responsible for over 2,000,000 confirmed cases and over 126,000 deaths worldwide. In this study, we examined the immunogenicity of CHO-expressed recombinant SARS-CoV-2 S1-Fc fusion protein in mice, rabbits, and monkeys as a potential candidate for a COVID-19 vaccine. We demonstrate that the S1-Fc fusion protein is extremely immunogenic, as evidenced by strong antibody titers observed by day 7. Strong virus neutralizing activity was observed on day 14 in rabbits immunized with the S1-Fc fusion protein using a pseudovirus neutralization assay. Most importantly, in <20 days and three injections of the S1-Fc fusion protein, two monkeys developed higher virus neutralizing titers than a recovered COVID-19 patient in a live SARS-CoV-2 infection assay. Our data strongly suggests that the CHO-expressed SARS-CoV-2 S1-Fc recombinant protein could be a strong candidate for vaccine development against COVID-19. (C) 2020 The Authors. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据